Patricia Rayman
0000-0003-2206-370X
Cleveland Clinic
24 papers found
Refreshing results…
Figure S3 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Table S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Figure S2 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Figure S4 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Table S3 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Data from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Table S6 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Table S5 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Figure S1 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Table S2 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Table S1 from Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma
Supplementary Table S3 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Figure S3 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Figure S2 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Table S2 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Table S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Data from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Figure S5 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Figure S4 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Supplementary Figure S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Missing publications? Search for publications with a matching author name.